Bad Timing for AstraZeneca's Good Data

While everybody was busy covering the sour clinical-trial news surrounding Merck (NYSE: MRK  ) and Schering-Plough's (NYSE: SGP  ) cholesterol fighter Vytorin earlier in the week, AstraZeneca (NYSE: AZN  ) quietly announced heart-throbbing news for its own cholesterol-lowering drug, Crestor.

AstraZeneca announced on Monday that a data-monitoring board decided to halt a Crestor trial early, so that placebo-treated patients could get access to it as well. The study was using Crestor to help prevent cardiovascular-related deaths and ailments, and the efficacy data was coming in strong. This was no small study, either -- it had more than 15,000 participants.

The timing couldn't have been worse for AstraZeneca. Vytorin -- a combination of Merck's Zocor and Schering's Zetia -- stole all of the headlines this week, and investors shaved billions of dollars off both companies' market caps. But even so, AstraZeneca needed the good news it got, since generic competition against its Toprol-XL compound has eaten into its sales this year. And the study results should give the company new ammunition in its marketing battles against the other statins, including Pfizer's (NYSE: PFE  ) Lipitor and even Zocor, which has now gone generic.

Crestor won approval in the U.S. in 2003 and has since become AstraZeneca's top-selling drug, with sales of $2.8 billion last year. That's a 38% increase over 2006, and it's nearly twice as much as what it takes in for Toprol-XL, its next highest-grossing compound.

We didn't get any details on the Crestor study results yesterday, except for the top-line announcement. But we do know that AstraZeneca's guidance for adjusted earnings per share this year was in the range of $4.40 to $4.70, just pennies above the $4.38 it earned in 2007. The company is also still integrating last year's MedImmune acquisition into its operations. However, with the positive Crestor news and the negative results from its competitors, we could see AstraZeneca raise its earnings guidance for the year when it reports its first-quarter financial results later this month.

Check out this Foolishness:

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 612171, ~/Articles/ArticleHandler.aspx, 10/24/2016 5:14:06 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 days ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:03 PM
AZN $30.72 Down -0.28 -0.90%
AstraZeneca CAPS Rating: ****
MRK $61.20 Down -0.72 -1.16%
Merck and Co. CAPS Rating: ****
PFE $32.18 Down -0.36 -1.11%
Pfizer CAPS Rating: ****
SGP.DL2 $28.15 Down +0.00 +0.00%
Schering-Plough Co… CAPS Rating: ****